Faster global financial news!
Johnson & Johnson
-
Merger talks between UK medical technology company Smith & Nephew and Johnson & Johnson's orthopedic division have broken down due to a dispute over leadership, with Smith & Nephew refusing to have the combined business led by a former J&J CEO.
Merger talks between UK medical technology company Smith & Nephew and Johnson & Johnson's orthopedic division have broken down due to a dispute over leadership, with Smith & Nephew refusing to have th
-
Johnson & Johnson raises profit guidance on strong demand for new drugs
Johnson & Johnson (JNJ) shares are moving as the company reported earnings, raising its profit guidance due to strong demand for newer drugs in cancer and autoimmune diseases, which offset slower grow
-
Yahoo Finance Analysis: Coca-Cola, Johnson & Johnson, and PepsiCo are three dividend stocks worth holding for Baby Boomers.
Yahoo Finance analysis indicates that Coca-Cola (KO), Johnson & Johnson (JNJ), and PepsiCo (PEP) are three dividend stocks suitable for Baby Boomer investors to hold for life. These companies boast de
-
Johnson & Johnson Targets Double-Digit Growth by End of Decade, Projects Over $100 Billion Revenue in 2026
Johnson & Johnson raised its growth ambitions, forecasting 6.5% adjusted operational sales growth and 7.3% adjusted EPS growth in 2026, with revenue expected to surpass $100 billion for the first time
-
Johnson & Johnson MedTech Chairman Tim Schmid: Confident in High-End Growth, Cardiovascular to Be Largest Business by Q1 2027
Johnson & Johnson (JNJ) MedTech Chairman Tim Schmid stated the company is confident in achieving the high end of its 5% to 7% operational market-growth range for 2022-2027. He highlighted a portfolio
-
LB Pharmaceuticals (LBRX) IPO Stock Has Tripled In Under A Year, Prompting Speculation It Could Be A Takeover Target
The small biotech company, which is based in New York, has one drug called LB-102, an oral formulation of the antipsychotic benzamide, and is working to challenge Bristol Myers Squibb (BMY) and Johnso
-
Yahoo Finance: Coca-Cola, Johnson & Johnson, and Procter & Gamble are 'Dividend Kings' trusted by retirees
According to Yahoo Finance analysis, Coca-Cola (KO), Johnson & Johnson (JNJ), and Procter & Gamble (PG) have consistently increased dividends through every U.S. recession since 1970, making them relia
-
Analysis shows Johnson & Johnson's latest 13F filing reveals holdings in 15 biotech stocks, with Protagonist Therapeutics being the largest investment, whose stock price has surged 65% year-to-date.
According to Yahoo Finance analysis, Johnson & Johnson's latest 13F filing (as of June 30, 2026) disclosed its holdings of 15 stocks in the biotechnology and medical technology sectors. The analysis i
-
AbbVie is considered a better healthcare stock pick than Johnson & Johnson for 2026, with its net income projected to surge to $14.6 billion.
An analysis from Yahoo Finance highlights AbbVie's impressive R&D pipeline and higher upside potential, projecting its net income to surge from $4.2 billion to $14.6 billion this fiscal year, with sal
-
Seaport Therapeutics (SPTX) is attracting interest from large pharmaceutical companies after its IPO, with its lead candidate drug GlyphAllo expected to announce Phase 2b topline data in the first half of 2027.
Analysis indicates that biopharmaceutical company Seaport Therapeutics (SPTX) has attracted attention from major pharmaceutical companies such as Bristol Myers Squibb (BMY) and Johnson & Johnson (JNJ)
-
Yahoo Finance analysis points out that three healthcare stocks, Eli Lilly, Johnson & Johnson, and AbbVie, are worth watching in August due to their relatively poor market performance but strong fundamentals.
The analysis suggests that although the healthcare sector has underperformed the S&P 500 year-to-date, it has led all sectors over the past three months. Specifically, Eli Lilly's Q2 revenue increased
-
Analysis identifies Johnson & Johnson, Coca-Cola, and ExxonMobil as top dividend stock buys for H2 2026
An analysis suggests Johnson & Johnson (JNJ), Coca-Cola (KO), and ExxonMobil (XOM) are strong dividend stock buys for the second half of 2026. The report highlights their consistent dividend growth, r
-
Merger talks between UK medical technology company Smith & Nephew and Johnson & Johnson's orthopedic division have broken down due to a dispute over leadership, with Smith & Nephew refusing to have the combined business led by a former J&J CEO.
Merger talks between UK medical technology company Smith & Nephew and Johnson & Johnson's orthopedic division have broken down due to a dispute over leadership, with Smith & Nephew refusing to have th
-
Johnson & Johnson raises profit guidance on strong demand for new drugs
Johnson & Johnson (JNJ) shares are moving as the company reported earnings, raising its profit guidance due to strong demand for newer drugs in cancer and autoimmune diseases, which offset slower grow
-
Yahoo Finance Analysis: Coca-Cola, Johnson & Johnson, and PepsiCo are three dividend stocks worth holding for Baby Boomers.
Yahoo Finance analysis indicates that Coca-Cola (KO), Johnson & Johnson (JNJ), and PepsiCo (PEP) are three dividend stocks suitable for Baby Boomer investors to hold for life. These companies boast de
-
Johnson & Johnson Targets Double-Digit Growth by End of Decade, Projects Over $100 Billion Revenue in 2026
Johnson & Johnson raised its growth ambitions, forecasting 6.5% adjusted operational sales growth and 7.3% adjusted EPS growth in 2026, with revenue expected to surpass $100 billion for the first time
-
Johnson & Johnson MedTech Chairman Tim Schmid: Confident in High-End Growth, Cardiovascular to Be Largest Business by Q1 2027
Johnson & Johnson (JNJ) MedTech Chairman Tim Schmid stated the company is confident in achieving the high end of its 5% to 7% operational market-growth range for 2022-2027. He highlighted a portfolio
-
LB Pharmaceuticals (LBRX) IPO Stock Has Tripled In Under A Year, Prompting Speculation It Could Be A Takeover Target
The small biotech company, which is based in New York, has one drug called LB-102, an oral formulation of the antipsychotic benzamide, and is working to challenge Bristol Myers Squibb (BMY) and Johnso
-
Yahoo Finance: Coca-Cola, Johnson & Johnson, and Procter & Gamble are 'Dividend Kings' trusted by retirees
According to Yahoo Finance analysis, Coca-Cola (KO), Johnson & Johnson (JNJ), and Procter & Gamble (PG) have consistently increased dividends through every U.S. recession since 1970, making them relia
-
Analysis shows Johnson & Johnson's latest 13F filing reveals holdings in 15 biotech stocks, with Protagonist Therapeutics being the largest investment, whose stock price has surged 65% year-to-date.
According to Yahoo Finance analysis, Johnson & Johnson's latest 13F filing (as of June 30, 2026) disclosed its holdings of 15 stocks in the biotechnology and medical technology sectors. The analysis i
-
AbbVie is considered a better healthcare stock pick than Johnson & Johnson for 2026, with its net income projected to surge to $14.6 billion.
An analysis from Yahoo Finance highlights AbbVie's impressive R&D pipeline and higher upside potential, projecting its net income to surge from $4.2 billion to $14.6 billion this fiscal year, with sal
-
Seaport Therapeutics (SPTX) is attracting interest from large pharmaceutical companies after its IPO, with its lead candidate drug GlyphAllo expected to announce Phase 2b topline data in the first half of 2027.
Analysis indicates that biopharmaceutical company Seaport Therapeutics (SPTX) has attracted attention from major pharmaceutical companies such as Bristol Myers Squibb (BMY) and Johnson & Johnson (JNJ)
-
Yahoo Finance analysis points out that three healthcare stocks, Eli Lilly, Johnson & Johnson, and AbbVie, are worth watching in August due to their relatively poor market performance but strong fundamentals.
The analysis suggests that although the healthcare sector has underperformed the S&P 500 year-to-date, it has led all sectors over the past three months. Specifically, Eli Lilly's Q2 revenue increased
-
Analysis identifies Johnson & Johnson, Coca-Cola, and ExxonMobil as top dividend stock buys for H2 2026
An analysis suggests Johnson & Johnson (JNJ), Coca-Cola (KO), and ExxonMobil (XOM) are strong dividend stock buys for the second half of 2026. The report highlights their consistent dividend growth, r
- No data
Johnson & Johnson
24H Trending
-
1
Bitcoin Price Breaks $77,000: Multiple Factors Drive Current Rally
-
2
US banks are owed $349B by private credit funds, as PIK interest payments rise to 10% of loans
-
3
Al Jazeera: Israeli attacks on Gaza kill at least 4 Palestinians, UN Human Rights Office warns of ethnic cleansing risk
-
4
Musk retweeted that as of October 31, the number of Starlink satellites has reached 11,184, accounting for 66% of the total active satellites globally.
-
5
Bitcoin Spot ETF Status Review: Market Impact and Latest Data Post-Approval
-
6
Bitcoin staking protocol b14g says $97 million CORE drained, pauses contracts
-
7
Nikkei Asia: Overseas entities' JPY bond issuance reaches a record $16 billion as the AI funding race spreads to Japan
-
8
Al Jazeera: Palestinian Man Succumbs to Injuries After Israeli Drone Strike in Gaza
-
9
SpaceXAI, the AI division of SpaceX, failed to dismiss an air pollution lawsuit filed by the NAACP, with the judge ruling that the case will proceed.
-
10
Binance confirmed that it has transferred 7,499 Bitcoins to the SAFU fund, stating that it has recovered 90% of the stolen assets and pledged to rebuild the emergency fund to approximately $1 billion.
Markets Today
Recommended Reading
Hot Topics
Svmuu focuses on blockchain industry trends and cutting-edge cryptocurrency news, while also covering real-time market data and in-depth analysis of the Hong Kong, U.S., and foreign exchange markets. Here, you can not only access professional 24/7 news updates and accurate market data, but also utilize practical investment tools to help you capitalize on opportunities in both digital assets and traditional financial markets. Whether you are a blockchain enthusiast or an investor in Hong Kong, U.S., or foreign exchange markets, we provide efficient and timely information services to empower your investment decisions.
- User Agreement
- Privacy Policy
- Contact Us
- Business Partnerships
- Disclaimer
- Content Statement
- About Us
- Sitemap
Coming Soon!
